Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 89 of 537 for:    "Skin cancer"

Measurement of the Partial Pressure of Oxygen in Cutaneous Tumors Using Electron Paramagnetic Resonance (EPR) Oximetry

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03716193
Recruitment Status : Not yet recruiting
First Posted : October 23, 2018
Last Update Posted : March 28, 2019
Sponsor:
Collaborators:
West Virginia Clinical and Translational Science Institute
Mary Babb Randolph Cancer Center at West Virginia University Hospitals
Information provided by (Responsible Party):
West Virginia University

Brief Summary:
This protocol will take measurements of a variety of tumors involving the skin in order to assess changes in tumor oxygen from hyperoxygenation therapy and standard cancer-directed treatments, to demonstrate the clinical feasibility of using in vivo Electron Paramagnetic Resonance (EPR) Oximetry to obtain clinically useful measurements of tumor oxygen levels from cancer patients.

Condition or disease Intervention/treatment Phase
Skin Lesion Skin Cancer Skin Melanoma Tumor Skin Other: Oxygen Not Applicable

Detailed Description:

All patients in this study will receive standard of care therapy for their cancer at the discretion of their treating physician(s). All subjects will be assigned to one of the four cohorts for which they qualify; there is no randomization and no stratification within the cohorts.

Cohort 1 - Patients who will receive definitive surgery for a primary malignancy of the skin

Cohort 2 - Patients who will receive definitive radiation (+/- concurrent systemic therapy) for a primary malignancy of the skin

Cohort 3 - Patients who will receive palliative radiation (+/- concurrent systemic therapy) for any tumor involving the skin

Cohort 4 - Patients who will receive systemic therapy alone (without radiation) for any tumor involving the skin

All patients enrolled in this study will undergo two initial measurements of their tumor oxygen level. On the first day, a small metal disc (less than 1 cm in diameter) called a SPOTChip will be placed on the surface of the tumor, and held in place using an adhesive. The patient will then be positioned (lying down or sitting) between a set of two magnets that are used to measure the oxygen level in the tumor. A small plastic oxygen detector will be placed on the skin over the tumor. These devices will be used to take a measurement of the tumor's oxygen level at baseline, then while breathing oxygen through a clear plastic facemask, and then a final time after the oxygen facemask has been removed.

After the measurements are taken, a small amount (20-50 microliters) of India ink will be injected into the tumor using a small (28-gauge) needle. The India ink will make a permanent, dark blue/black colored mark on the tumor. The ink leaves a permanent tattoo in the spot where it is injected, unless it is physically removed surgically.

The patient will return for another measurement, at least 2 days later. This measurement will use the India ink that was previously injected (described above) and there will no longer be a need to use the SPOTChip. For the India ink tumor oxygen measurement a small piece of wire (called a loop resonator) will be placed over the tumor and held in place using medical honey and saran wrap or tape. The Investigator will first take a measurement of the tumor's oxygen level at baseline, then while breathing oxygen through a clear plastic facemask, and then the mask will be taken the tumor's oxygen level will be measured as it returns to baseline.

Patients who have surgical excision of the tumor (cohort 1) will not have any further measurements after this point.

Patients who are being treated with radiation therapy (cohorts 2 & 3), will come back for weekly measurements of the tumor during treatment, followed by one additional measurement one month after they have completed the course of radiation therapy.

Patients being treated with chemotherapy, immunotherapy, or other systemic therapies without radiation (cohort 4), will come back for measurements every 3-4 weeks around the time of their regular infusion, followed by one additional measurement one month after they complete the course of systemic therapy.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Four cohorts based on standard treatment will be given the same intervention
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Measurement of the Partial Pressure of Oxygen in Cutaneous Tumors Using Electron Paramagnetic Resonance (EPR) Oximetry
Estimated Study Start Date : May 1, 2019
Estimated Primary Completion Date : January 1, 2020
Estimated Study Completion Date : January 1, 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Cohort 1
Patients who will receive definitive surgery for a primary malignancy of the skin, will have their tumor injected with India ink for tumor marking and will be given oxygen during the measurement sessions.
Other: Oxygen
Patients will be given oxygen via a facemask during the measurement session

Experimental: Cohort 2
Patients who will receive definitive radiation (+/- concurrent systemic therapy) for a primary malignancy of the skin, will have their tumor injected with India ink for tumor marking and will be given oxygen during the measurement sessions.
Other: Oxygen
Patients will be given oxygen via a facemask during the measurement session

Experimental: Cohort 3
Patients who will receive palliative radiation (+/- concurrent systemic therapy) for any tumor involving the skin, will have their tumor injected with India ink for tumor marking and will be given oxygen during the measurement sessions.
Other: Oxygen
Patients will be given oxygen via a facemask during the measurement session

Experimental: Cohort 4
Patients who will receive systemic therapy alone (without radiation) for any tumor involving the skin, will have their tumor injected with India ink for tumor marking and will be given oxygen during the measurement sessions.
Other: Oxygen
Patients will be given oxygen via a facemask during the measurement session




Primary Outcome Measures :
  1. Assess the change in oxygenation of cutaneous tumors from hyperoxygenation therapy during the standard therapy for the disease [ Time Frame: From the first oxygen measurement to one month after the completing standard therapy ]
    Tumor oxygen kinetics will be measured by EPR oximetry under ambient conditions, during hyperoxygenation therapy (100% O2 administered via a non-rebreather face mask), and immediately after hyperoxygenation therapy.


Secondary Outcome Measures :
  1. To characterize temporal variations in oxygenation of cutaneous tumors over a course of local radiation therapy and/or systemic chemotherapy or immunotherapy [ Time Frame: From the first oxygen measurement to one month after the completing standard therapy ]
    Patients will undergo weekly tumor oxygen measurements by EPR during a radiation therapy course and every 3-4 week measurements during cycles of systemic therapy. Changes in tumor oxygen will be correlated with standard measures of response to therapy using RECIST criteria.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Pathology-proven (histology or cytology) malignancy of any histology and site of origin
  • Visible tumor (primary or metastasis) involving the skin of at least 6 mm in diameter
  • Negative serum or urine pregnancy test within 72 hours prior to registration for women of childbearing potential

Exclusion Criteria:

  • Implanted electric, magnetic or mechanically activated devices like a pacemaker, defibrillator, nerve stimulator, cochlear implant or portable infusion pump. Also individuals who have any non-MRI compatible implants
  • Individuals who have a ferromagnetic foreign body located in their body
  • Prior adverse reaction to a charcoal product (e.g., a local hypersensitive response from a black tattoo or from ingestion of activated charcoal)
  • Prior adverse reaction to gum Arabic, which is an ingredient in the India ink
  • Prior allergic reaction to medical adhesives
  • Psychiatric illness/social situations that would limit compliance with study requirements
  • Pregnant or lactating women. There is no known harm to the woman or her fetus from participating; this is precautionary only

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03716193


Contacts
Layout table for location contacts
Contact: Malcolm Mattes, MD 304-598-4706 mdmattes@hsc.wvu.edu
Contact: Sylvia McEwuen, RN 304-293-1683 smcewuen@hsc.wvu.edu

Locations
Layout table for location information
United States, West Virginia
WVU Cancer Institute - Mary Babb Randolph Cancer Center Not yet recruiting
Morgantown, West Virginia, United States, 26506
Contact: Malcolm Mattes, MD    304-598-4706    mdmattes@hsc.wvu.edu   
Contact: Sylvia McEwuen, RN    304-293-1683    smcewuen@hsc.wvu.edu   
Principal Investigator: Malcolm Mattes, MD         
Sub-Investigator: Andrey Bobko, PhD         
Sub-Investigator: Timothy Eubank, PhD         
Sub-Investigator: Geraldine Jacobson, MD         
Sub-Investigator: Valery Khramtsov, PhD         
Sub-Investigator: Mark Tseytlin, PhD         
Sponsors and Collaborators
West Virginia University
West Virginia Clinical and Translational Science Institute
Mary Babb Randolph Cancer Center at West Virginia University Hospitals
Investigators
Layout table for investigator information
Principal Investigator: Malcolm Mattes, MD West Virginia University
  Study Documents (Full-Text)

Documents provided by West Virginia University:
Informed Consent Form  [PDF] June 13, 2018


Layout table for additonal information
Responsible Party: West Virginia University
ClinicalTrials.gov Identifier: NCT03716193     History of Changes
Other Study ID Numbers: WVU011118
First Posted: October 23, 2018    Key Record Dates
Last Update Posted: March 28, 2019
Last Verified: March 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Skin Neoplasms
Neoplasms by Site
Neoplasms
Skin Diseases